



MEDIA RELEASE: Sydney, Australia. Wednesday, 5 June 2013.

PHEBRA'S NEW ENERGY EFFICIENCY PROGRAM

Australian pharmaceutical firm Phebra is “going green” by implementing a wide-ranging energy efficiency program at its new Sydney sterile manufacturing plant to dramatically reduce its carbon footprint.

The installation of new lighting, cooling and energy management systems throughout the plant at Lane Cove West will result in an estimated saving of estimated **328 tonnes of carbon** each year for the company.

In the warehouse, new LED light fittings will cut current energy consumption by more than 70 per cent alone, while a “Smartcool” air conditioning system will save 20 per cent.

Phebra’s Chief Executive Officer, Dr Mal Eutick, said the project was part of Phebra’s ongoing commitment to reducing energy and emissions during day to day manufacturing and operations at the plant – officially opened in March by Federal Minister for Climate Change, Industry and Innovation, Greg Combet.

“The new plant has provided Phebra with a wonderful opportunity to firstly measure the company’s energy usage and then look at innovative ways of reducing our emissions and improving cost efficiencies across the business,” Dr Eutick said today.

“We have already been encouraged by the estimated 328 tonnes of carbon that Phebra will save each year and believe the new system will lay the foundation for sustainable manufacturing processes for us well into the future.”

Stage One of the project, undertaken by Sydney firm **Green Energy Technical Services (GETS)**, includes new T5 and emergency LED light fittings in the car park, offices and throughout the building; a sensor energy management system to ensure lighting is only used when required; a “green clock” displayed in the foyer to show the amount of CO₂ emissions saved each day – streamed live on the Phebra and GETS websites, and training for Phebra staff by GETS on ways to reduce energy consumption.

“Upon the completion of the current program, we will be looking at the installation of solar panelling on the roof of the plant as well as undertaking a water conservation audit to identify ways Phebra can save on water,” Dr Eutick added.



ABOUT PHEBRA

Phebra is an Australian specialty pharmaceutical company that develops manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

Phebra's range of critical medicines, currently supplied across the Australian hospital system, covers a range of pharmaceuticals in important disease areas such as cystic fibrosis, antidotes, diagnostics, oncology, pain and emergency drugs.

At Phebra, we create critical medicines that save and improve lives.

Media contact:
Richard Lenarduzzi at The Premier Communications Group
+61 2 9223 3075
info@premiercomms.com.au